<DOC>
	<DOC>NCT00850993</DOC>
	<brief_summary>The purpose of this study is to determine if an experimental drug, stannsoporfin, is safe and effective in the treatment of hyperbilirubinemia in hemolyzing neonates.</brief_summary>
	<brief_title>A Safety and Efficacy Trial of Stannsoporfin in Neonates With Hyperbilirubinemia</brief_title>
	<detailed_description />
	<mesh_term>Hyperbilirubinemia</mesh_term>
	<mesh_term>Hyperbilirubinemia, Neonatal</mesh_term>
	<mesh_term>Tin mesoporphyrin</mesh_term>
	<criteria>Term and late preterm subjects Risk factors for hemolytic disease to include ABO blood type incompatibility or Rh incompatibility (antiC, c, D, E, or e, or G6PD deficiency A minimum birth weight of 2500 g (5.5 lbs) Enrollment within 2 mg/dL below the Total Serum Bilirubin (TSB) threshold for PhotoTherapy (PT) per the AAP Guidelines at up to 12 hours of age or within 3 mg/dL below the threshold for PhotoTherapy (PT) at &gt;12 to 48 hours of age, inclusive Randomization and treatment cannot take place until the infant is within 1 mg/dl below the threshold for PhotoTherapy (PT) per the American Association Pediatrics (AAP) Guidelines at up to 12 hours of age or within 2 mg/dL below the threshold for PT at &gt;12 to 48 hours of age, inclusive Treatment or need for treatment in the neonate with medications that may prolong the QT interval, family history of Long QT syndrome or family history of Sudden Infant Death Syndrome Risk factors for porphyrias, including family history Apgar score â‰¤6 at age 5 minutes Significant congenital anomalies or infections Cardiorespiratory distress Any abnormal auditory or ophthalmologic findings Any excess risk of requiring surgery or exposure to operating room lights in the foreseeable future Clinically significant abnormalities on screening laboratory evaluation Use of photosensitizing drugs or agents Use of intravenous immunoglobulin (IVIG) or albumins Other serious morbid conditions, eg, pulmonary disease, cardiovascular disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>48 Hours</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Hemolysis</keyword>
</DOC>